These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33433422)

  • 1. Hepatoid adenocarcinoma of lung: A diagnostic challenge - Series of six cases with histopathological, predictive molecular and PD.L1 assessment.
    Pasricha S; Grover S; Kamboj M; Bansal D; Batra U; Gupta G; Sharma A; Durga G; Jajodia A; B Koyyala VP; Mehta A
    Indian J Pathol Microbiol; 2021; 64(1):128-131. PubMed ID: 33433422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.
    Xu K; Gao J; Feng L; Fang Y; Tang X
    Front Immunol; 2023; 14():1203876. PubMed ID: 37292208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginase-1 is frequently positive in hepatoid adenocarcinomas.
    Chandan VS; Shah SS; Torbenson MS; Wu TT
    Hum Pathol; 2016 Sep; 55():11-6. PubMed ID: 27137985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases.
    Terracciano LM; Glatz K; Mhawech P; Vasei M; Lehmann FS; Vecchione R; Tornillo L
    Am J Surg Pathol; 2003 Oct; 27(10):1302-12. PubMed ID: 14508391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature.
    Haninger DM; Kloecker GH; Bousamra Ii M; Nowacki MR; Slone SP
    Mod Pathol; 2014 Apr; 27(4):535-42. PubMed ID: 24030743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
    Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
    Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
    Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
    J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
    Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
    Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
    J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. About PD-L1 Immunohistochemistry and RNA In Situ Hybridization in Lung Adenocarcinoma.
    Uguen A
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):e9-e10. PubMed ID: 29494400
    [No Abstract]   [Full Text] [Related]  

  • 14. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
    Lee SE; Kim YJ; Sung M; Lee MS; Han J; Kim HK; Choi YL
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
    Liu L; Ruiz J; O'Neill SS; Grant SC; Petty WJ; Yang M; Chen K; Topaloglu U; Pasche B; Zhang W
    Mol Cancer; 2018 Apr; 17(1):81. PubMed ID: 29650000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatoid adenocarcinoma of the lung: Review of a rare form of lung cancer.
    Grossman K; Beasley MB; Braman SS
    Respir Med; 2016 Oct; 119():175-179. PubMed ID: 27692141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Predictive Value of
    Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
    Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
    [No Abstract]   [Full Text] [Related]  

  • 20. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.